by Dr. Ed Weber | May 28, 2021 | PCa Commentary
Radioligand Therapy (RLT) targeted with the radionuclide Lutetium 177 or Actinium 225 has been found in early studies to be promising, safe and effective. A Gestault of results has generally shown about a 50% PSA decline in 50% of patients and a median... by Dr. Ed Weber | Apr 13, 2021 | PCa Commentary
Genomic classifier panels for risk stratification and whole-genome sequencing in search of actionable mutations both provide personal molecular data that can guide management decisions. However, each provides an entirely different category of information. Both are... by Dr. Ed Weber | Mar 25, 2021 | PCa Commentary
Metastases Directed Therapy (MDT) has become a realistic option for men who develop metastases after primary therapy. The theoretical foundation of MDT was succinctly stated by David Palma, M.D., PhD: “The oligometastatic paradigm hypothesizes that... by Dr. Ed Weber | Feb 25, 2021 | PCa Commentary
A Commentary discussing bone health and bone protective therapy may not be as eye-catching as new developments in PSMA and Axumin imaging or radioligand therapy with Lu-177, but as the old spiritual says: “dem bones, dem bones gonna walk around …” and we... by Dr. Ed Weber | Feb 3, 2021 | PCa Commentary
A great deal has been written about the comparison between Lupron (leuprolide) and Firmagon (degarelix). Lupron as been the mainstay of treatment of relapsed and metastatic prostate cancer since its introduction in the early 1990’s. Firmagon (degarelix) was FDA...